Atovaquone

Atovaquone is filed as Antimalarial [EPC]. The sections below restate public label fields stored for this profile.

Class
Antimalarial [EPC]
Route
ORAL
Dosage forms
3 DOSAGE FORMS AND STRENGTHS Atovaquone oral suspension, USP is a yellow homogenous suspension containing 750 mg of atovaquone USP per 5 mL. Atovaquone oral suspension, USP is supplied in 210 mL bottles. Oral suspension: 750 mg per 5 mL ( 3 )
Generic available
Yes
Manufacturer
Lupin Pharmaceuticals, Inc.

Approved uses

1 INDICATIONS AND USAGE Atovaquone oral suspension is a quinone antimicrobial drug indicated for: Prevention of Pneumocystis jirovecii pneumonia (PCP) in adults and adolescents aged 13 years and older who cannot tolerate trimethoprim-sulfamethoxazole (TMP-SMX). ( 1.1 ) Treatment of mild-to-moderate PCP in adults and adolescents aged 13 years and older who cannot tolerate TMP-SMX. ( 1.2 ) Limitations of Use ( 1.3 ): Treatment of severe PCP (alveolar arterial oxygen diffusion gradient [(A-a)DO 2 ] >45 mm Hg) with atovaquone oral suspension has not been studied. The efficacy of atovaquone oral suspension in subjects who are failing therapy with TMP-SMX has also not been studied. 1.1 Prevention of Pneumocystis jirovecii Pneumonia Atovaquone oral suspension is indicated for the prevention of Pneumocystis jirovecii pneumonia (PCP) in adults and adolescents (aged 13 years and older) who cannot tolerate trimethoprim-sulfamethoxazole (TMP-SMX). 1.2 Treatment of Mild-to-Moderate Pneumocystis jirovecii Pneumonia Atovaquone oral suspension is indicated for the acute oral treatment of mild-to-moderate PCP in adults and adolescents (aged 13 years and older) who cannot tolerate TMP-SMX. 1.3 Limitations of Use Clinical experience with atovaquone for the treatment of PCP has been limited to subjects with mild-to-moderate PCP (alveolar-arterial oxygen diffusion gradient [(A-a)DO 2 ] ≤45 mm Hg). Treatment of more severe episodes of PCP with atovaquone has not been studied. The efficacy of atovaquone in subjects who are failing therapy with TMP-SMX has also not been studied.

How it works

12.1 Mechanism of Action Atovaquone is a quinone antimicrobial drug [see Clinical Pharmacology ( 12.4 )] .

Warnings and precautions

5 WARNINGS AND PRECAUTIONS Failure to administer atovaquone oral suspension with food may result in lower plasma atovaquone concentrations and may limit response to therapy. Patients with gastrointestinal disorders may have limited absorption resulting in suboptimal atovaquone concentrations. (5.1) Hepatotoxicity: Elevated liver chemistry tests and cases of hepatitis and fatal liver failure have been reported. (5.2) Severe Cutaneous Adverse Reactions (SCARs): Cases of SCARs such as Stevens-Johnson Syndrome (SJS) have been reported. SCARs can be life-threatening or fatal. If symptoms or signs of SCARs develop, discontinue atovaquone immediately and institute appropriate therapy. (5.3) 5.1 Risk of Limited Oral Absorption Absorption of orally administered atovaquone oral suspension is limited but can be significantly increased when the drug is taken with food. Failure to administer atovaquone oral suspension with food may result in lower plasma atovaquone concentrations and may limit response to therapy. Consider therapy with other agents in patients who have difficulty taking atovaquone oral suspension with food or in patients who have gastrointestinal disorders that may limit absorption of oral medications [see Clinical Pharmacology (12.3) ]. 5.2 Hepatotoxicity Cases of cholestatic hepatitis, elevated liver enzymes, and fatal liver failure have been reported in patients treated with atovaquone [see Adverse Reactions (6.2) ]. If treating patients with severe hepatic impairment, closely monitor patients following administration of atovaquone. 5.3 Severe Cutaneous Adverse Reactions Cases of severe cutaneous adverse reactions (SCARs), including Stevens-Johnson Syndrome (SJS), drug reaction with eosinophilia and systemic symptoms (DRESS), and erythema multiforme (EM) have been reported in patients treated with atovaquone [see Adverse Reactions (6.2) ] . SCARs can be life-threatening or fatal. If symptoms or signs of SCARs develop, discontinue atovaquone immediately and institute appropriate therapy. Patients who have developed SCARs with the use of atovaquone must not receive atovaquone [see Contraindications (4) ] .

Contraindications

4 CONTRAINDICATIONS Atovaquone oral suspension is contraindicated in patients who develop or have a history of hypersensitivity reactions (e.g., angioedema, bronchospasm, throat tightness, urticaria) to atovaquone or any of the components of atovaquone oral suspension. Known serious allergic/hypersensitivity reaction (e.g., angioedema, bronchospasm, throat tightness, urticaria) to atovaquone or any of the components of atovaquone oral suspension. ( 4 )

Common side effects

The majority of subjects were white (64%); Male (88%); Ving prophylaxis for pcp at randomization (73%); Percentage (>2%); Rimary prophylaxis patients at enrollment (58%); S treated with atovaquone oral suspension (46%); Ects treated with aerosolized pentamidine (28%); Mg once daily were rash (6%)

Adverse reactions

The following clinically significant adverse reactions are discussed in another section of the labeling: • Vomiting and Diarrhea [see Warnings and Precautions ( 5.1 )]. • Hepatotoxicity [see Warnings and Precautions ( 5.3 )]. • Severe Cutaneous Adverse Reactions [see Warnings and Precautions ( 5.4 )].

Dosage and administration

2 DOSAGE AND ADMINISTRATION Prevention of PCP: 1,500 mg (10 mL) once daily with food ( 2.1 ) Treatment of PCP: 750 mg (5 mL) twice daily with food for 21 days ( 2.2 ) Supplied in Bottles: Shake bottle gently before use. ( 2.3 ) 2.1 Dosage for the Prevention of P. jirovecii Pneumonia The recommended oral dosage is 1,500 mg (10 mL) once daily administered with food. 2.2 Dosage for the Treatment of Mild-to-Moderate P. jirovecii Pneumonia The recommended oral dosage is 750 mg (5 mL) twice daily (total daily dose = 1,500 mg) administered with food for 21 days. 2.3 Important Administration Instructions Administer atovaquone oral suspension with food to avoid lower plasma atovaquone concentrations that may limit response to therapy [see Warnings and Precautions ( 5.1), Clinical Pharmacology ( 12.3 )] . Atovaquone Oral Suspension Bottle Shake bottle gently before administering the recommended dosage.

Drug interactions

7 DRUG INTERACTIONS Concomitant administration of rifampin or rifabutin reduces atovaquone concentrations; concomitant use with atovaquone oral suspension is not recommended. ( 7.1 ) Concomitant administration of tetracycline reduces atovaquone concentrations; use caution when coadministering. Monitor patients for potential loss of efficacy of atovaquone if coadministration of tetracycline is necessary. ( 7.2 ) Concomitant administration with metoclopramide reduces atovaquone concentrations; administer concomitantly only if other antiemetics are not available. ( 7.3 ) Concomitant administration of indinavir reduces indinavir trough concentrations; use caution when coadministering. Monitor patients for potential loss of efficacy of indinavir if coadministration is necessary. ( 7.4 ) 7.1 Rifampin/Rifabutin Concomitant administration of rifampin or rifabutin and atovaquone oral suspension is known to reduce atovaquone concentrations [see Clinical Pharmacology ( 12.3 )] . Concomitant administration of atovaquone oral suspension and rifampin or rifabutin is not recommended. 7.2 Tetracycline Concomitant administration of tetracycline and atovaquone oral suspension has been associated with a reduction in plasma concentrations of atovaquone [see Clinical Pharmacology ( 12.3 )]. Caution should be used when prescribing tetracycline concomitantly with atovaquone oral suspension. Monitor patients for potential loss of efficacy of atovaquone if coadministration is necessary. 7.3 Metoclopramide Metoclopramide may reduce the bioavailability of atovaquone and should be used only if other antiemetics are not available [see Clinical Pharmacology ( 12.3 )]. 7.4 Indinavir Concomitant administration of atovaquone and indinavir did not result in any change in the steady-state AUC and C max of indinavir but resulted in a decrease in the C trough of indinavir [see Clinical Pharmacology ( 12.3 )]. Caution should be exercised when prescribing atovaquone oral suspension with indinavir due to the decrease in trough concentrations of indinavir. Monitor patients for potential loss of efficacy of indinavir if coadministration with atovaquone oral suspension is necessary.

Common questions

What is Atovaquone approved to treat?

According to its FDA label, Atovaquone is approved for: 1 INDICATIONS AND USAGE Atovaquone oral suspension is a quinone antimicrobial drug indicated for: Prevention of Pneumocystis jirovecii pneumonia (PCP) in adults and adolescents aged 13 years and older who cannot tolerate trimethoprim-sulfamethoxazole (TMP-SMX). ( 1.1 ) Treatment… For medical advice, please talk to your prescriber or pharmacist.

What class of drug is Atovaquone?

Atovaquone belongs to the Antimalarial [EPC] class of medications.

What form does Atovaquone come in?

The FDA label lists Atovaquone as: 3 DOSAGE FORMS AND STRENGTHS Atovaquone oral suspension, USP is a yellow homogenous suspension containing 750 mg of atovaquone USP per 5 mL. Atovaquone oral suspension, USP is supplied in 210 mL bottles. Oral suspension: 750 mg per 5 mL ( 3 ); oral route. Available strengths and packaging vary by manufacturer.

Is there a generic version of Atovaquone?

Yes. A generic version of Atovaquone is available in the U.S. Ask your pharmacist about substitution.

Does Atovaquone have a Boxed Warning?

Our ingest of the FDA label for Atovaquone does not include a Boxed Warning at this time. See the full label on DailyMed for the current, authoritative version.

How much does Atovaquone cost?

Public CMS NADAC pricing for Atovaquone is in the range Retail prices vary widely by pharmacy, insurance, and location. Check with your pharmacy or use tools like GoodRx for current pricing.. Retail price varies by pharmacy, insurance, and manufacturer coupons.

Is Atovaquone currently under recall?

The FDA Enforcement Report does not show an active/ongoing recall for Atovaquone in our latest ingest. Recall data can change daily — verify at FDA.gov.

When was Atovaquone approved by the FDA?

The FDA record lists the approval date for Atovaquone as 2018-10-11.

Who makes Atovaquone?

The FDA label lists Lupin Pharmaceuticals, Inc. as a labeler/manufacturer of Atovaquone. Multiple firms may market generics of the same molecule.

How should Atovaquone be stored?

The FDA label states: "Atovaquone oral suspension, USP is a bright yellow, citrus-flavored, oral suspension. It is supplied in the following: NDC 81033-105-05: 5 mL unit-dose cup NDC 81033-105-22: Carton containing 20 unit-dose cups of 5 mL ea…" Follow the packaging insert for the authoritative guidance.

What is the pregnancy category for Atovaquone?

The FDA label lists a pregnancy category of C for Atovaquone. Pregnancy and lactation decisions should be made with a clinician.

On this site

Related medications in this class or category

Loading full data from Know Your Drugs Institute…